Needham & Company LLC Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $130.00

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective decreased by Needham & Company LLC from $139.00 to $130.00 in a research note released on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Other analysts also recently issued reports about the stock. Citigroup reiterated an “outperform” rating on shares of Rhythm Pharmaceuticals in a research report on Friday, December 12th. Wells Fargo & Company raised their price target on shares of Rhythm Pharmaceuticals from $136.00 to $143.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Guggenheim lifted their price target on Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a “buy” rating in a report on Friday, February 27th. HC Wainwright reduced their price objective on Rhythm Pharmaceuticals from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Monday, March 2nd. Finally, Morgan Stanley decreased their price objective on Rhythm Pharmaceuticals from $150.00 to $136.00 and set an “overweight” rating for the company in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $131.13.

Rhythm Pharmaceuticals Price Performance

Shares of RYTM opened at $90.31 on Tuesday. Rhythm Pharmaceuticals has a 12 month low of $45.90 and a 12 month high of $122.20. The stock has a fifty day moving average price of $99.31 and a 200 day moving average price of $102.60. The company has a market cap of $6.17 billion, a P/E ratio of -29.04 and a beta of 2.06.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.The company had revenue of $57.25 million for the quarter, compared to analysts’ expectations of $56.16 million. During the same period last year, the business posted ($0.72) earnings per share. The firm’s quarterly revenue was up 36.9% compared to the same quarter last year. As a group, research analysts anticipate that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current year.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other news, CAO Christopher Paul German sold 5,614 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total transaction of $502,789.84. Following the sale, the chief accounting officer owned 160 shares in the company, valued at $14,329.60. The trade was a 97.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Hunter C. Smith sold 4,385 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the transaction, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at $11,190,445.12. This represents a 3.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 27,267 shares of company stock valued at $2,719,955. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Rhythm Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC boosted its position in shares of Rhythm Pharmaceuticals by 303.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock worth $28,000 after buying an additional 200 shares during the period. Smartleaf Asset Management LLC raised its position in Rhythm Pharmaceuticals by 97.2% during the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after buying an additional 141 shares during the period. Farther Finance Advisors LLC raised its position in Rhythm Pharmaceuticals by 1,110.3% during the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock valued at $35,000 after buying an additional 322 shares during the period. Optiver Holding B.V. lifted its stake in Rhythm Pharmaceuticals by 65.2% in the 3rd quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock worth $37,000 after acquiring an additional 144 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its position in Rhythm Pharmaceuticals by 73.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock worth $37,000 after acquiring an additional 145 shares during the period.

Key Headlines Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: FDA approval for a new indication — The FDA approved IMCIVREE® (setmelanotide) for patients with acquired hypothalamic obesity, making it the first and only approved therapy for this rare, difficult‑to‑treat condition; this expands the commercial opportunity and is the primary catalyst for the stock rally today. FDA Approval Release
• Positive Sentiment: Some broker price targets remain elevated — An American Banking News aggregation shows broker price targets (one cited at $133.19), which supports upside narratives among buy‑side holders. Broker PT Coverage
• Neutral Sentiment: HC Wainwright trims price target but keeps a Buy — HC Wainwright lowered its PT to $100 (from $110) and continues to rate RYTM a Buy, which tempers the bullish view though still implying upside from current levels. Coverage Note
• Neutral Sentiment: Valuation commentary after share weakness — Coverage pieces are reassessing valuation given recent volatility and long‑term returns; useful context for investors thinking about entry points. Valuation Article
• Negative Sentiment: Late‑stage trial failure for a lead indication — Rhythm reported a late‑stage weight‑loss trial setback for IMCIVREE in certain rare obesity populations, a development that previously drove shares lower and raises questions about broader label expansion and near‑term upside. Trial Failure Report
• Negative Sentiment: Multiple firms issue pessimistic forecasts / lower expectations — Bank of America and RBC published negative outlooks, and Citizens JMP and Needham also lowered expectations; these analyst moves increase downward pressure and suggest elevated near‑term volatility. Bank of America Forecast RBC Forecast Citizens JMP Needham
• Negative Sentiment: HC Wainwright lowered near‑term EPS estimate — The firm reduced its Q3 2027 EPS forecast (to $0.33 from $0.42), signaling tempered near‑term revenue/earnings visibility despite the approval and ongoing commercialization work.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.